Merck
Develops oncology medicines, vaccines, cardiopulmonary therapies, and animal-health products worldwide.
$148.19
After-hours close−0.12 (−0.08%)
At close$148.31(−0.82%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 101.77%Insiders 0.04%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 2.47B · Float 2.47B · 99.8% free float
Institutions13F, as of Jun 30, 2026
3,928 holders · 2.51B shares · 214 new positions · 1,833 increased · 1,506 reduced · 186 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 227.00M | 9.19% | +1.17M | Aug 7, 2026 |
| Vanguard Capital Management LLC | 161.32M | 6.53% | +335.6K | Aug 13, 2026 |
| State Street Corp | 120.41M | 4.88% | +1.09M | Aug 7, 2026 |
| Wellington Management Group LLP | 86.25M | 3.49% | +1.93M | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 67.74M | 2.74% | +434.7K | Aug 13, 2026 |
| Geode Capital Management, LLC | 60.74M | 2.46% | +1.19M | Aug 12, 2026 |
| Sixth Street Partners Management Company, L.P. | 54.37M | 2.20% | +54.37Mnew | Aug 14, 2026 |
| Charles Schwab Investment Management Inc | 54.37M | 2.20% | +4.60M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Vanguard Capital Management | 7.53% | 186.32M | 13G | Apr 30, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Robert M. Davis | director, officer: Chairman, CEO & President | 450.4K | 0.02% | May 1, 2026 |
| Richard R. DeLuca | officer: EVP&Pres, Merck Animal Heallth | 110.2K | 0.00% | Aug 12, 2026 |
| Dean Y. Li | officer: Executive VP & President, MRL | 94.4K | 0.00% | May 1, 2026 |
| Caroline Litchfield | officer: EVP & CFO | 92.3K | 0.00% | May 1, 2026 |
| David Michael Williams | officer: EVP,Chief Info&Digital Officer | 66.4K | 0.00% | Aug 7, 2026 |
| Jennifer Zachary | officer: EVP, General Counsel | 45.5K | 0.00% | Aug 13, 2026 |
| Chirfi Guindo | officer: EVP, Access, Policy & Comms | 36.6K | 0.00% | Aug 13, 2026 |
| Joseph Romanelli | officer: President, Human Health Int?l | 28.7K | 0.00% | Jan 28, 2026 |
| Johannes Jacobus Oosthuizen | officer: EVP, Oncology & Int?l | 21.9K | 0.00% | May 1, 2026 |
| David R. Maraldo | officer: EVP & Pres. MMD | 20.9K | 0.00% | Aug 7, 2026 |
70 people have not refiled in the last 18 months (3.41M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 13, 2026 | Chirfi Guindoofficer: EVP, Access, Policy & Comms | Sale | 10,000 | $135.00 | 36,613 |
| Aug 12, 2026 | Jennifer Zacharyofficer: EVP, General Counsel | Sale | 80,315 | $133.46 | 45,509 |
| Aug 12, 2026 | Richard R. DeLucaofficer: EVP&Pres, Merck Animal Heallth | Sale · 2 lots | 11,699 | $131.63 | 110,167 |
| Aug 11, 2026 | Richard R. DeLucaofficer: EVP&Pres, Merck Animal Heallth | Sale · 2 lots | 12,837 | $131.76 | 121,866 |
| Aug 10, 2026 | Richard R. DeLucaofficer: EVP&Pres, Merck Animal Heallth | Sale | 20,784 | $130.43 | 134,703 |
| Aug 6, 2026 | Richard R. DeLucaofficer: EVP&Pres, Merck Animal Heallth | Sale · 3 lots | 6,050 | $130.38 | 155,487 |
| Aug 6, 2026 | Chirfi Guindoofficer: EVP, Access, Policy & Comms | Sale | 15,000 | $131.00 | 46,613 |
| Aug 5, 2026 | David Michael Williamsofficer: EVP,Chief Info&Digital Officer | Sale | 34,705 | $128.77 | 31,716 |
| Aug 5, 2026 | David R. Maraldoofficer: EVP & Pres. MMD | Sale | 2,686 | $128.72 | 18,212 |
| Feb 12, 2026 | Chirfi Guindoofficer: Chief Marketing Officer | Sale | 10,000 | $121.46 | 60,615 |
CongressHouse and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Rep. Keith Self | Sale | $1,001 – $15,000 | Self | Jan 10, 2025 | Jul 1, 2026 ↗ |